SEC Form RW filed by Cel-Sci Corporation

5/27/26 5:00:36 PM ET

$CVM

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CVM alert in real time by email

RW 1 cvm_rw.htm FORM RW cvm_rw.htm

CEL-SCI CORPORATION

8229 Boone Blvd. #802

Vienna, VA 22182

(703) 506-9460

May 27, 2026

Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549

	Re:	CEL-SCI Corporation
		Post-Effective Amendment to Registration Statement on Form S-3
		File No. 333-265995

CEL-SCI Corporation (the “Company”) requests that the above-captioned registration statement be withdrawn. The reason for this request is that the Post-Effective Amendment was filed in error.

No securities were sold by means of the Post-Effective Amendment to the Registration Statement.

	Very Truly Yours,

	CEL-SCI CORPORATION

	/s/ Geert R. Kersten
	Geert R. Kersten
	Chief Executive Officer

WTH:tg

Get the next $CVM alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$CVM

Date	Price Target	Rating	Analyst

More analyst ratings

$CVM
Press Releases

Fastest customizable press release news feed in the world

View All

CEL-SCI Reports Fiscal Second Quarter 2026 Results

On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026 Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia 50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation CEL-SCI's CEO continues to invest in the Company acquiring a cumulative ~$930,000 worth of stock over the past 10 months CEL-SCI Corporation (NYSE:CVM) today reported financial results for three months ended March 31, 2026, as well as key recent corporate, commercial, regulatory, and clinical developments for Multikine (Leukocyte Interleukin, Injection)*. "Durin

5/18/26 8:00:00 AM ET

$CVM

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

CEL-SCI Announces Closing of Public Offering

CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts public offering of 6,000,000 shares of its common stock. Each share of common stock was sold at a public offering price of $1.20 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $7.2 million. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offering. A registration statement on

5/13/26 3:00:00 PM ET

$CVM

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

CEL-SCI Corporation Announces Pricing of Public Offering

CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000 shares of its common stock at an offering price of $1.20 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and offering expenses, are expected to be approximately $7.2 million. The offering is expected to close on May 13, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the proceeds for the continued development of Multikine*, general corporate purposes, and working capital. ThinkEquity is acting as the sole placement agen

5/11/26 8:11:00 PM ET

$CVM

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

$CVM
Leadership Updates

Live Leadership Updates

View All

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This

8/15/24 8:00:00 AM ET

$CVM

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

CEL-SCI Appoints Robert Watson as Chairperson of the Board

CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in

7/8/24 9:15:00 AM ET

$CVM

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation

4/23/24 9:00:00 AM ET

$CVM

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

SEC Form RW filed by Cel-Sci Corporation

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CVM

SEC Form RW filed by Cel-Sci Corporation

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CVM

$CVM
Press Releases

CEL-SCI Reports Fiscal Second Quarter 2026 Results

CEL-SCI Announces Closing of Public Offering

CEL-SCI Corporation Announces Pricing of Public Offering

$CVM
Insider Purchases

$CVM
Insider Trading

Chief Executive Officer Kersten Geert R bought $360,000 worth of shares (300,000 units at $1.20) (SEC Form 4)

Chief Executive Officer Kersten Geert R bought $119,000 worth of shares (100,000 units at $1.19), increasing direct ownership by 82% to 222,497 units (SEC Form 4)

Chief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)

Chief Executive Officer Kersten Geert R bought $360,000 worth of shares (300,000 units at $1.20) (SEC Form 4)

Chief Executive Officer Kersten Geert R bought $119,000 worth of shares (100,000 units at $1.19), increasing direct ownership by 82% to 222,497 units (SEC Form 4)

SEC Form 4 filed by Talor Eyal

$CVM
SEC Filings